Current Report · Items 8.01 · 8-K
Vaxart, Inc
Other Events
Item 8.01 Other Events. On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee.…
Filed Aug 25, 2026Accepted Aug 25, 2026, 4:12 PM EDTCIK 72444Accession 0001437749-26-028916
Company context
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Current securities
Historical securities (2)
Disclosure sections
Items 8.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On August 21, 2026, the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), upon the recommendation of the Nominating and Governance Committee, formed two new committees of the Board: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee.
The Clinical and Regulatory Affairs Committee is responsible among other responsibilities, for reviewing and providing oversight and advice regarding the Company’s research, clinical, and regulatory programs on behalf of the Board. James B. Breitmeyer, M.D., Ph. D. and David Wheadon, M.D. were appointed as members of the Clinical and Regulatory Affairs Committee, with Dr. Breitmeyer serving as Chair.
The Stockholder Engagement Committee is responsible, among other responsibilities, for overseeing the advancement of the Company’s relations with stockholders. W. Mark Watson and Steven Lo were appointed as members of the Stockholder Engagement Committee, with Mr. Watson serving as Interim Chair. Pursuant to that certain Cooperation Agreement, dated as of July 1, 2026, entered into between the Company and the other parties thereto, the Company anticipates appointing a new director to the Board in the future who will serve as Chair of the Stockholder Engagement Committee.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including with respect to the anticipated appointment of a new director. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements.
